Use of antitumor necrosis factors in juvenile idiopathic arthritis

Authors

  • Bruno Leal Carneiro Intern of the 12th period at the School of Medicine of the University of Grande Rio (UNIGRANRIO)
  • Alessandra Fonseca Physicians and researchers associated with the Rheumatology Sector of the Center for Studies on Adolescent Health (NESA) of the Pedro Ernesto University Hospital of the State University of Rio de Janeiro (HUPE/UERJ)
  • Luciene Lima Campos Physician responsible for the Rheumatology Sector of NESA from HUPE/UERJ; assistant professor of Pediatric Rheumatology at UNIGRANRIO; professor at the Department of Pediatrics at the Federal University of Rio de Janeiro (UFRJ)
  • Henrique d’Abreu Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002;62(17):2493-537
  • Flavio R. Sztajnbok Arend WP, ​​Gabay C. Cytokines in the rheumatic diseases. Rheum Dis Clin North Am 2004;30(1):41-67

Keywords:

juvenile idiopathic arthritis, anti-tumor necrosis factor, etanercept, infliximab, adverse effects

Abstract

Juvenile idiopathic arthritis is the most common chronic rheumatologic disease in childhood, and is an important cause of deformities and functional impotence. Physical and drug therapies can be used to treat this disease. In this article, we will review the use of anti-tumor necrosis factor (anti-TNF) drugs in juvenile idiopathic arthritis, describing their efficacy, dosage, and main side effects. We searched for articles in journals and textbooks that addressed the topic, using the most recent ones as the main criterion for selection. Two drugs in this class have been approved for use in children, infliximab and etanercept, and are indicated for those patients in whom conventional treatment of this disease has not been satisfactory. Side effects include infections at the injection site, respiratory infections, and increased susceptibility to granulomatous diseases, including reactivation of tuberculosis. These drugs play an important role in controlling the disease, in addition to improving patients’ daily activities, and, despite side effects, they can be used safely when indicated. juvenile idiopathic arthritis; anti-tumor necrosis factor; etanercept; infliximab; adverse effects

Downloads

How to Cite

Carneiro, B. L., Fonseca, A., Campos, L. L., d’Abreu, H., & Sztajnbok, F. R. (2005). Use of antitumor necrosis factors in juvenile idiopathic arthritis. Adolescência E Saúde, 2(4), 21–25. Retrieved from https://adolescenciaesaude.com/index.php/aes/article/view/95

Issue

Vol. 2 No. 4 (2005): Vol. 2 No. 4 (2005)

Section

Original Articles

License

Copyright (c) 2005 Universidade do Estado do Rio de Janeiro

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.